Development of peptide therapeutics: A nonclinical safety assessment perspective.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Development of peptide therapeutics: A nonclinical safety assessment perspective.
- Published In:
- Regulatory toxicology and pharmacology : RTP, 117, 104766 (2020)
- Authors:
- Mitra, Mayur S, DeMarco, Steven, Holub, Brad, Thiruneelakantapillai, Lakshmanan, Thackaberry, Evan A
- Database ID:
- RPEP-05004
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-05004APA
Mitra, Mayur S; DeMarco, Steven; Holub, Brad; Thiruneelakantapillai, Lakshmanan; Thackaberry, Evan A. (2020). Development of peptide therapeutics: A nonclinical safety assessment perspective.. Regulatory toxicology and pharmacology : RTP, 117, 104766. https://doi.org/10.1016/j.yrtph.2020.104766
MLA
Mitra, Mayur S, et al. "Development of peptide therapeutics: A nonclinical safety assessment perspective.." Regulatory toxicology and pharmacology : RTP, 2020. https://doi.org/10.1016/j.yrtph.2020.104766
RethinkPeptides
RethinkPeptides Research Database. "Development of peptide therapeutics: A nonclinical safety as..." RPEP-05004. Retrieved from https://rethinkpeptides.com/research/mitra-2020-development-of-peptide-therapeutics
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.